Treatment of Dupuytren's disease using one full dose of Clostridiumhistolyticum collagenase at a lower concentration: Retrospective analysis of clinical outcomes.

Abstract

Clostridiumhistolyticum collagenase (CHC) is rapidly becoming a mainstream treatment option for Dupuytren's disease for hand surgeons. We performed a retrospective study of the efficacy of this substance at a lower concentration, but a higher total dose than recommended by the manufacturer. Thirty-nine patients with 43 affected hands were treated and analyzed at a mean follow-up of 27 months. Subgroup analysis was done for patients who received treatment in one or two joints (group A), and for patients who received treatment in more than two joints (group B). We found that our CHC solution is safe and effective when simultaneously treating as many as four joints affected by Dupuytren's disease. Patients in group B had a lower (but non-significant) treatment failure rate compared to patients in group A. Also, higher satisfaction rates were observed in group B, again non-significant. No major complications were observed in any group. CHC use is associated with only minor complications. The results are consistent even when up to four joints are treated with one dose. LEVEL OF EVIDENCE: III.

• Authors: Y Goubau, B Vanmierlo, C-K Goorens, J F Goubau
• Journal: Hand surgery & rehabilitation (Hand Surg Rehabil) Vol. 39 Issue 4 Pg. 316-319 (09 2020) ISSN: 2468-1210 [Electronic] France
• PMID: 32259595 (Publication Type: Journal Article)
• Copyright: Copyright © 2020 SFCM. Published by Elsevier Masson SAS. All rights reserved.

Chemical References

• Microbial Collagenase

Topics

• Disease Progression
• Dose-Response Relationship, Drug
• Dupuytren Contracture (therapy)
• Follow-Up Studies
• Humans
• Injections
• Microbial Collagenase (administration & dosage)
• Patient Satisfaction
• Retrospective Studies